Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05122754Phase 4Unknown

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

Role: collaborator

NCT03884673Recruiting

Dolutegravir Plus Lamivudine Simplified Therapy

Role: collaborator

NCT03852849Not ApplicableUnknown

Rapid Build of HIV Related Protective Barriers

Role: collaborator

NCT01318096Not ApplicableUnknown

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

Role: lead

All 4 trials loaded